PMC:7195088 / 59981-60353 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"1778","span":{"begin":216,"end":224},"obj":"Species"},{"id":"1783","span":{"begin":141,"end":170},"obj":"Disease"}],"attributes":[{"id":"A1778","pred":"tao:has_database_id","subj":"1778","obj":"Tax:9606"},{"id":"A1783","pred":"tao:has_database_id","subj":"1783","obj":"MESH:D001424"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":", 95% CI 1.3–2.4; p 0.0002), increased length of ICU stay (mean difference: 2.1, 95% CI 1.2–3.1; p \u003c 0.0001) and increased rate of secondary bacterial or fungal infection (risk ratio: 2.0, 95% CI 1.0–3.8; p 0.04) in patients who received corticosteroids [66].\n\nQuestion 5 statement\nSo far, no definitive efficacy or effectiveness data are available on the benefit of corti"}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T342","span":{"begin":154,"end":170},"obj":"Disease"},{"id":"T343","span":{"begin":161,"end":170},"obj":"Disease"}],"attributes":[{"id":"A342","pred":"mondo_id","subj":"T342","obj":"http://purl.obolibrary.org/obo/MONDO_0002041"},{"id":"A343","pred":"mondo_id","subj":"T343","obj":"http://purl.obolibrary.org/obo/MONDO_0005550"}],"text":", 95% CI 1.3–2.4; p 0.0002), increased length of ICU stay (mean difference: 2.1, 95% CI 1.2–3.1; p \u003c 0.0001) and increased rate of secondary bacterial or fungal infection (risk ratio: 2.0, 95% CI 1.0–3.8; p 0.04) in patients who received corticosteroids [66].\n\nQuestion 5 statement\nSo far, no definitive efficacy or effectiveness data are available on the benefit of corti"}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T70959","span":{"begin":238,"end":253},"obj":"Chemical"}],"attributes":[{"id":"A89095","pred":"chebi_id","subj":"T70959","obj":"http://purl.obolibrary.org/obo/CHEBI_50858"}],"text":", 95% CI 1.3–2.4; p 0.0002), increased length of ICU stay (mean difference: 2.1, 95% CI 1.2–3.1; p \u003c 0.0001) and increased rate of secondary bacterial or fungal infection (risk ratio: 2.0, 95% CI 1.0–3.8; p 0.04) in patients who received corticosteroids [66].\n\nQuestion 5 statement\nSo far, no definitive efficacy or effectiveness data are available on the benefit of corti"}

{"project":"LitCovid-sentences","denotations":[{"id":"T438","span":{"begin":76,"end":183},"obj":"Sentence"},{"id":"T439","span":{"begin":184,"end":259},"obj":"Sentence"},{"id":"T440","span":{"begin":261,"end":281},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":", 95% CI 1.3–2.4; p 0.0002), increased length of ICU stay (mean difference: 2.1, 95% CI 1.2–3.1; p \u003c 0.0001) and increased rate of secondary bacterial or fungal infection (risk ratio: 2.0, 95% CI 1.0–3.8; p 0.04) in patients who received corticosteroids [66].\n\nQuestion 5 statement\nSo far, no definitive efficacy or effectiveness data are available on the benefit of corti"}

{"project":"2_test","denotations":[{"id":"32360444-30917856-22369806","span":{"begin":255,"end":257},"obj":"30917856"}],"text":", 95% CI 1.3–2.4; p 0.0002), increased length of ICU stay (mean difference: 2.1, 95% CI 1.2–3.1; p \u003c 0.0001) and increased rate of secondary bacterial or fungal infection (risk ratio: 2.0, 95% CI 1.0–3.8; p 0.04) in patients who received corticosteroids [66].\n\nQuestion 5 statement\nSo far, no definitive efficacy or effectiveness data are available on the benefit of corti"}